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Introduction
Platinum-based doublet regimens have been a mainstay of first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) since a landmark meta-analysis clearly demonstrated a significant survival benefit compared with best supportive care (1, 2) .
The 2009 American Society of Clinical Oncology guidelines recommended no further chemotherapy after first-line chemotherapy prior to disease progression (DP) for patients who have stable disease or who respond to first-line therapy (3, 4) . The paradigm is shifting, however, following the introduction of newer, less-toxic agents including pemetrexed and erlotinib. Extending the duration of first-line chemotherapy by immediately starting early effective second-line or switch maintenance therapy with these agents has become a valid approach in the treatment of patients with advanced NSCLC (3, 4) .
Concerns have arisen, however, about the toxicities and additional costs associated with chemotherapy administered in a non-curative setting to patients with a disease with poor prognosis (5) . There may be a subset of patients with relatively less aggressive disease who may be over-treated by an immediate transition to further treatment after first-line therapy. To date, however, no study has reliably identified these patients (6) . F-fluoro-2-deoxy-glucose positron emission tomography (FDG-PET) could facilitate response-adapted therapy and reduce overall healthcare costs by reducing the use of, and complications associated with unnecessary treatment (7, 8) . Reduction of metabolic activity after chemotherapy in advanced NSCLC was closely correlated with patient outcome (9, 10).
Thus, we hypothesized that FDG-PET may be a useful determinant in identifying a subgroup of patients with better prognosis who may be spared immediate maintenance therapy until disease progression. To determine whether metabolic response as determined by FDG-PET, in this specific context of maintenance therapy after first-line chemotherapy, may discriminate patients with longer time to progression (TTP), we performed FDG-PET before and after four cycles of chemotherapy in patients with stage IV NSCLC who did not progress after first-line platinum-based chemotherapy.
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Patients and Methods

Patients and Treatments
Forty three patients with advanced NSCLC patients who underwent baseline FDG-PET and did not show evidence of DP after a fourth cycle of first-line platinum based chemotherapy were enrolled in this study. Patients were not further treated until DP. All patients had pathologically confirmed NSCLC stage IV, as determined by the 7th edition of the American Joint Committee on Cancer staging system, measurable lesions, age ≥18 years, and Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. Enrollment of patients who received radiotherapy to non-target lesion before primary chemotherapy was allowed. Patients having asymptomatic or treated brain metastases were eligible. Patients with previous or concurrent cancer that was distinct in primary site or histology from NSCLC, except for cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors, were excluded, as were pregnant or breast-feeding women. Uncontrolled diabetic patients were excluded. The study protocol was approved by the Institutional Review Board of the Asan Medical Center, and written informed consent was obtained from all patients. 
FDG-PET imaging
Baseline FDG-PET was performed 1-7 days before initiation of chemotherapy and a second FDG-PET was repeated 3 weeks after the fourth cycle of chemotherapy. Patients fasted for at least 6 hours before the examination to maintain serum glucose concentrations <150 mg/dL. Scanning began 60 ± 10 minutes after intravenous injection of 7. mass using vendor's software, and a maximum SUV (SUVmax) was obtained using the single maximum pixel count within the VOI. Peak SUV (SUVpeak) was defined as a mean of SUV in a sphere with a diameter of 1.5 cm centering on the SUVmax (11) . Metabolic changes during chemotherapy were compared with the main lesion and used as indicators of disease status.
If all lesions had disappeared, VOIs were drawn in the same areas on baseline and interim FDG-PET scans, comparing slices carefully and ensuring that the VOI was restricted to the baseline tumor.
Statistical considerations
The primary end point was to compare percent decrease in SUVmax in patients with TTP ≥8 weeks (late DP subgroup) and those with TTP <8 weeks (early DP subgroup). The secondary end points were to determine whether metabolic response assessed by percent decrease in SUVmax could predict TTP and OS. TTP was calculated from the date of second FDG-PET examination to the date of documented progression or last follow-up. Deaths unrelated to disease progression were censored. OS was calculated from the date of second FDG-PET examination to the date of death from any cause or last follow-up. Both TTP and OS were calculated using the Kaplan-Meier method. We calculated sample size by assuming that the median TTP in the early and late DP subgroups would be 6 weeks and 14 weeks, 10 respectively. We therefore calculated that a sample size of 38 patients would provide 80% power at a 10% two-sided significance level for patients recruited within 1 year and with a follow-up of the last patient of 14 weeks. We assumed a follow-up loss rate of 10%, thus requiring 43 patients. The Wilcoxon signed rank test was used to compare the percent decrease in SUVmax/peak between the early and late DP subgroups (12) . Receiver operating characteristic (ROC) curve analysis was used to define the optimal threshold of percent SUVmax/peak decrease that could discriminate between the early and late DP subgroups (13) . Kaplan-Meier curves and log-rank tests were used to assess the correlation of TTP and OS with the cutoff in percent SUVmax/peak decrease. Absolute SUVmax/peak and percent change in SUVmax/peak were expressed as means ± standard deviations. A p-value <0.05 was considered statistically significant. All 43 patients showed disease progression during follow-up and 41 of them were given second-line systemic treatment. While 5 patients developed new metastases, the others showed locoregional progression with (n=15) or without (n=23) systemic failure. Seventeen patients died; 16 due to DP and one due to pneumonia. At a median follow-up period of 15.6 months (range, 9.9-22.8 months) after the second FDG-PET examination for the surviving patients, the median TTP was 2.6 months (95% CI, 2.2-2.9 months) and the median OS was 20.1 months (95% CI, 12.5-27.8 months). We found that 27 patients were in the late DP subgroup and 16 were in the early DP group. The two groups did not differ in patient characteristics, including gender distribution, performance status, histopathologic subtypes, M stage and chemotherapy regimens, or in response to first-line chemotherapy ( Table 1 ). The median TTPs in these two subgroups were 3.2 months (95% CI, 2.6-3.8 months) and 1.5 months (95% CI, 1.4-1.5 months), respectively (p<0.001).
Evaluation by FDG-PET
Blood glucose levels at the first and second PET scan were 102.5 ± 14.1 mg/dL and 107.7 ± 17.7 mg/dL. Although five diabetic patients were included (two in the early DP group and three in the late DP group), their SUVmax did not differ from those of non-diabetic patients (Table A1, (Table A2 , online only). Tumor SUVs decreased significantly after four cycles of first-line chemotherapy (baseline SUVmax = 11.5 ± 5.2 vs post-chemotherapy SUVmax = 6.5 ± 6.1, p< 0.001). Percent changes in SUVmax differed significantly between the early DP (27.8 ± 46.8 %) and the late DP group (54.7% ± 27.2%) (p=0.021) (Table 2, Figure A1 , A2, online only). In the absence of an established cutoff value for SUVmax change, a ROC curve analysis defined a 50.0% decrease in SUVmax as the optimal threshold to distinguish the early and late DP groups. Using this value as the cutoff resulted in a sensitivity of 70.4%, a specificity of 75.0%, a positive predictive value (PPV) of 82.6%, a negative predictive value (NPV) of 60.0%, and an overall accuracy of 72.1% in predicting late DP (Table 3) .
TTP and OS according to FDG-PET metabolic responses
When we assorted patients based on a 50% decrease in SUVmax, we found that 23 patients were good metabolic responders (≥50.0% decrease in SUVmax) and 20 were poor metabolic responders (<50% decrease in SUVmax). The two groups did not significantly differ in patient characteristics (Table A3 ). The median TTPs in these two subgroups were 3.0 months (95% CI, 2.3-3.7 months) and 1.5 months (95% CI, 1.4-1.7 months), respectively (HR, 0.27, 95% CI 0.13-0.57, p=0.001) ( Figure 1A) . While a median OS was not reached in
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on (Table 4) . When a multivariate analysis was performed with these significant predictors of OS in univariate analyses, a 50% reduction in SUVmax was the only significant predictor of TTP (HR, 0.317; 95% CI, 0.158-0.639; p=0.001) and OS (HR, 0.251; 95% CI, 0.079-0.799; p=0.019) ( Table 5, Table A4 ).
Exploratory analysis with SUVpeak
We underwent exploratory analysis with SUVpeak. Fractional decrease in SUVpeak after primary chemotherapy was significantly higher in the late DP group (48.9% ± 25.7% vs 25.7% ± 45.9%, p=0.039) (Table 2, Figure A1 , online only). Decrease in SUVpeak of 50.0%
was the optimal cutoff to differentiate the early and late DP groups in a ROC curve analysis 
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resulting in PPV of 80.0% predicting late DP (Table 3) . Twenty patients showed superior metabolic response (≥50.0% decreases in SUVpeak). Decrease in SUVpeak by 50% was a significant predictor of both TTP (p=0.012) and OS (p=0.012) (Table 4 and Figure A3 received docetaxel was similar to that in the immediate docetaxel arm in Fidias' study (16) .These findings raise the question of whether the survival benefit would have been preserved if more patients in the placebo arm had received second-line treatments. It is therefore not clear whether optimum treatment should involve use of this maintenance strategy or whether it is better to wait until progression of disease to start second-line therapy.
However, FDA approved both pemetrexed and erlotinib for the purpose and this therapeutic approach is also enlisted in current National Comprehensive Cancer Network (NCCN) guidelines for the treatment of lung cancer (v3.2011). The strategy of immediate maintenance therapy is presently adopted by at least a party of physicians. It would be therefore worthwhile to identify patients who do and do not require immediate maintenance therapy.
A meta-analysis showed that the metabolic activity of the primary tumor, as determined by SUV on FDG-PET imaging, was a prognostic factor in patients with NSCLC (17) . Fractional decreases in SUV following chemotherapy, ranging from 20% to 50%, were also able to prognostically stratify these patients (9, 10, 18, 19) . One issue that must be addressed is the optimal timing of serial FDG-PET. In patients with locally advanced NSCLC, interim FDG-PET after one cycle of neoadjuvant chemotherapy was able to discriminate among patients with different prognoses (9, 20 However, none of the studies, to our knowledge, have investigated the role of FDG-PET in selecting patients for maintenance therapy and our study showed that FDG-PET scan results could identify patients with TTP ≥8 and <8 weeks. We chose an 8-week cutoff because [6] [7] [8] weeks is the usual timing for evaluation after first-line chemotherapy and a difference in TTP between the maintenance and observation arms ranged from 1 to 3 months (3, 4, 15), making it the optimal minimum chemotherapy holiday.
A ≥50% decrease in SUVmax, as the threshold for a FDG-PET response, could differentiate patients into early and late DP subgroups, with a positive predictive value of 82.6% for the prediction of late DP. This indicates that at least more than 80% of patients do not progress early without maintenance chemotherapy if their fractional decrease in SUVmax exceeds 50%. Close follow-up of patients, however, is still required not to lose the opportunity of second line treatment in those who progress early despite good metabolic responses. We also found that both median TTP and OS were significantly longer in the FDG-PET responders than in non-responders, while anatomic response according to RECIST (i.e., SD vs PR) could not predict both TTP and OS. In addition to SUVmax, we performed exploratory analysis with SUVpeak which is the average SUV within a finite volume around the maximum pixel value as the concept was introduced in the PET Response Criteria in Solid Tumors
Research. (11) . Fractional decrease in SUVpeak was also significantly higher in the late DP group and 50% decrease in SUVpeak following primary chemotherapy could distinguish the late DP from the early DP group with a PPV of 80.0%, which are consistent with results from SUVmax change. Taken together, evaluation of metabolic response by FDG-PET may be a potential tool in identifying patients with longer TTP who may be overtreated by an immediate transition to further treatment after first-line therapy. Thus, a ≥50% decrease in SUVmax or SUVpeak may be relevant reference criteria for future studies. This fractional change in SUVmax or SUVpeak may be a better cut-off than absolute value because the SUV thresholds identified in single-institution studies involving a specific set of patients may not be applicable to other institutions with different equipment, patient populations, and clinical imaging protocols (22).
Our findings suggest that comparison of FDG-PET before and after first-line chemotherapy can discriminate a subgroup of patients with longer TTP and predict both TTP and OS in patients with advanced NSCLC using a specific cut-off value of percent change in SUVmax or SUVpeak. This approach may represent a novel application of FDG-PET which has not been studied before. We defined the metabolic response criteria for prospective trials. 
